Insider Transactions Reported by 27 Insiders of Spyre Therapeutics, Inc.

Symbol
SYRE on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

Spyre Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Cameron Turtle Chief Executive Officer, Director $27,301,524 -$3,070,179 -10% 02 Mar 2026
Michael Thomas Henderson Director $5,523,583 21 Jan 2026
Scott L. Burrows Chief Financial Officer $4,082,430 -$401,259 -8.9% 03 Mar 2026
Jeffrey W. Albers Director $1,005,838 29 May 2025
Anthony G. Quinn President & CEO, Director $579,952 16 Mar 2022
Marcio Souza Director $63,900 25 Aug 2022
James Paul Kastenmayer General Counsel 23 Feb 2023
Linda L. Neuman Chief Medical Officer 23 Feb 2023
Jeff Marc Goldberg President and CEO, Director 29 Nov 2022
BAKER BROS. ADVISORS LP Director 08 Jun 2021
Alison Frances Lawton Director 22 Jun 2023
Armen Shanafelt Director 07 Jun 2022
Jonathan Alspaugh President and CFO 22 Jun 2023
Hunter C. Smith Director 22 Jun 2023
Jr. Michael Conick Hanley Chief Business Officer 23 Feb 2023
Leslie Sloan Chief Operating Officer 23 Aug 2022
Russell J. Cox Director 22 Jun 2023
Sandesh Mahatme Director 07 Jun 2022
Ivana Magovcevic-Liebisch Director 22 Jun 2023
Bryan Lawlis V Director 07 Jun 2022
Steven Weber VP, Controller&Princ Acctg Off 17 Feb 2022
Sandra Milligan Director 29 May 2025
Fairmount Funds Management LLC Director 29 May 2025
Sheldon Sloan Chief Medical Officer 09 Jan 2026
Heidy King-Jones Chief Legal Officer and Corporate Secretary 09 Jan 2026
Mark C. McKenna Director 29 May 2025
Laurie Stelzer Director 29 May 2025

Recent Insider Transactions by Companies or Individuals for Spyre Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Scott L. Burrows SYRE Common Stock Sale -2.49% $101,620 $40.65 -2,500 97,994 03 Mar 2026 Direct
Scott L. Burrows SYRE Common Stock Options Exercise 2.55% 2,500 100,494 03 Mar 2026 Direct
Scott L. Burrows SYRE Stock Option (Right to Buy) Options Exercise -0.62% -2,500 402,357 03 Mar 2026 Direct
Cameron Turtle SYRE Common Stock Sale -2.28% $632,866 $42.19 -15,000 642,540 02 Mar 2026 Direct
Cameron Turtle SYRE Common Stock Sale -2.23% $492,045 $32.80 -15,000 657,540 02 Feb 2026 Direct
Michael Thomas Henderson SYRE Common Stock Other 60% 63,227 168,606 21 Jan 2026 Direct
Scott L. Burrows SYRE Stock Option (Right to Buy) Award 140,000 140,000 09 Jan 2026 Direct
Cameron Turtle SYRE Stock Option (Right to Buy) Award 528,000 528,000 09 Jan 2026 Direct
Sheldon Sloan SYRE Stock Option (Right to Buy) Award 140,000 140,000 09 Jan 2026 Direct
Heidy King-Jones SYRE Stock Option (Right to Buy) Award 140,000 140,000 09 Jan 2026 Direct
Cameron Turtle SYRE Common Stock Sale -2.18% $460,134 $30.68 -15,000 671,907 02 Jan 2026 Direct
Cameron Turtle SYRE Common Stock Sale -2.14% $435,356 $29.02 -15,000 686,907 01 Dec 2025 Direct
Cameron Turtle SYRE Common Stock Sale -6.02% $1,049,778 $23.33 -45,000 701,907 03 Nov 2025 Direct
Scott L. Burrows SYRE Common Stock Sale -15.8% $299,639 $16.26 -18,428 97,994 02 Sep 2025 Direct
Fairmount Funds Management LLC SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 By Tomas Kiselak
Fairmount Funds Management LLC SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 By Peter Harwin
Laurie Stelzer SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 Direct
Sandra Milligan SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 Direct
Mark C. McKenna SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 Direct
Michael Thomas Henderson SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 Direct
Jeffrey W. Albers SYRE Stock Option (Right to Buy) Award 25,000 25,000 29 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.